ICU Medical (ICUI) Q4 2018 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2018 earnings summary
6 Nov, 2026Executive summary
2018 integration of Hospira Infusion Systems reached its final stages: unified commercial, manufacturing, supply-chain and IT platforms, with Pfizer transition services exited.
Profitability and cash generation improved; adjusted EBITDA was nearly $290M, and year-end cash and short-term investments were $382.1M with no borrowings.
Reported net income declined to $28.8M from $68.6M in 2017, amid $105.4M of restructuring and integration costs, a $41.6M contract settlement charge and a $20.4M earn-out fair-value charge.
Financial highlights
FY 2018 revenue was $1.400B; gross profit was $570.0M, operating income $21.6M, and net income $28.8M.
Operating cash flow was $160.2M versus $154.4M in 2017; cash, cash equivalents and short-term investments increased to $382.1M from $300.1M.
Q4 revenue was $340.4M; gross profit $134.6M; net loss $7.4M and diluted loss per share $0.36.
Q4 net loss included $41.1M in restructuring, strategic transaction and integration expenses; an additional $8.6M non-cash contract-settlement charge was recorded in the quarter.
ASC 606 adoption increased FY revenue by $11.1M and gross profit by $7.7M versus the prior standard; opening retained earnings rose $6.3M.
Outlook and guidance
FY 2019 capital expenditures were estimated at $95M–$105M, directed to manufacturing capacity, customer-placed infusion products and IT; cash and operating cash flow were expected to fund these investments.
2019 was expected to have a difficult first-half comparison due to IV Solutions shortages continuing into early 2018; integration cash costs were expected to continue at a much lower level.
Focus areas included segment positioning, operating stability after integration, R&D and longer-term capital deployment; product launches were expected to broaden offerings over the medium term.
Existing cash and expected operating cash flow were considered sufficient for operations over the next 12 months; no certainty was given for longer-term funding needs.
Latest events from ICU Medical
- Record revenue and cash flow, led by infusion and oncology, offset critical care pressure.ICUI
Q4 2011 - Record FY09 revenue and earnings accompanied a major shift to direct critical care sales.ICUI
Q4 2009 - Custom and direct-channel growth lifted 2010 results, while Hospira concentration remains a key risk.ICUI
Q4 2010 - Record revenue and stronger margins, offset by lower earnings and critical care sales.ICUI
Q4 2012 - Normalized IV Solutions demand cut FY19 revenue, while cash and integration savings supported resilience.ICUI
Q4 2019 - Record FY16 growth funded an infusion transformation, with integration the near-term test.ICUI
Q4 2016 - Record FY15 performance, with growth led by Infusion and Oncology and diversification still critical.ICUI
Q4 2015 - HIS expanded the portfolio, but integration costs drove a FY2017 operating loss.ICUI
Q4 2017 - Infusion Systems growth and record operating cash flow cushioned pandemic-driven weakness elsewhere.ICUI
Q4 2020